title: Towards understanding the aetiology and pathophysiology of the emetic reflex: novel approaches to antiemetic drugs.
abstract: The introduction of 5-HT3 antagonists, such as ondansetron, as antiemetic agents has transformed the management of patients receiving chemotherapy or radiation therapy. Studies in animal models with NK1 antagonists suggest that these represent a new class of antiemetic agents having a broader spectrum of activity than 5-HT3 antagonists. Compounds of this class may prove to be more effective in man against delayed emesis induced by cisplatin, post-operative nausea and vomiting and motion sickness. Thus, they have the potential to complement 5-HT3 antagonists and so provide a further advance in the management of nausea and vomiting.
authors.affiliation: Division of Biology, Glaxo Research and Development Ltd., Ware, Herts., UK.
authors.forename: C
authors.initials: C
authors.lastname: Bountra
authors.forename: J D
authors.initials: JD
authors.lastname: Gale
authors.forename: C J
authors.initials: CJ
authors.lastname: Gardner
authors.forename: C C
authors.initials: CC
authors.lastname: Jordan
authors.forename: G J
authors.initials: GJ
authors.lastname: Kilpatrick
authors.forename: D J
authors.initials: DJ
authors.lastname: Twissell
authors.forename: P
authors.initials: P
authors.lastname: Ward
mesh_terms: D000818:Animals; D000932:Antiemetics / Q000494:pharmacology / Q000627:therapeutic use*; D005544:Forecasting; D006801:Humans; D064729:Neurokinin-1 Receptor Antagonists; D012018:Reflex / Q000502:physiology; D014839:Vomiting / Q000209:etiology* / Q000503:physiopathology* / Q000517:prevention & control
chemical_list: D000932:Antiemetics; D064729:Neurokinin-1 Receptor Antagonists